| Literature DB >> 10984139 |
M Meissner1, Y Sherer, Y Levy, H Chwalinska-Sadowska, P Langevitz, Y Shoenfeld.
Abstract
The use of intravenous immunoglobulin (IVIg) has been reported as an immunomodulating agent in several autoimmune diseases, including systemic lupus erythematosus (SLE). Herein we report a SLE patient with severe clinical presentation that included pericarditis, pleural effusion, nephrotic range proteinuria, leukopenia, and lymphopenia. The patient received one course of high-dose IVIg (2.8 g/kg body weight), and within a week of post-IVIg therapy, her condition significantly improved. One-month post-IVIg there were decreased proteinuria, elevated leukocytes and lymphocytes count, decrease in antinuclear and anti-dsDNA antibodies, and disappearance of pericarditis and pleuritis. This case demonstrates the efficacy of IVIg in severe SLE with various clinical manifestations.Entities:
Mesh:
Substances:
Year: 2000 PMID: 10984139 DOI: 10.1007/s002960000053
Source DB: PubMed Journal: Rheumatol Int ISSN: 0172-8172 Impact factor: 2.631